Aug 5 (Reuters) - Drugmaker Mallinckrodt said on Monday

it will sell its Therakos business to CVC Capital Partners

for $925 million.

Dublin-based Mallinckrodt ( MCKPF ), which bought the business in 2015

for $1.33 billion, said it will use the proceeds from the deal

with CVC to reduce its debt by more than 50%.

Therakos' treatment is used to treat skin symptoms of a type

of cancer in people who are unresponsive to other types of

treatment.

Mallinckrodt ( MCKPF ), which makes branded and generic drugs, said in

November that it has emerged from bankruptcy.